Evidence map›Paper›PMID 35343355›Full record

ArticleCurrent eye research2022

Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System.

Kayla M Rudeen, Wenqiang Liu, William F Mieler, Jennifer J Kang-Mieler

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Kayla M RudeenDepartment of Biomedical Engineering, Illinois Institute of Technology, Chicago, USA.
Wenqiang LiuDepartment of Biomedical Engineering, Illinois Institute of Technology, Chicago, USA.
William F MielerDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, USA.
Jennifer J Kang-MielerDepartment of Biomedical Engineering, Illinois Institute of Technology, Chicago, USA.
Illinois Institute of Technology · USUniversity of Illinois Chicago · US

Funding

Sustained Ocular Drug Delivery System for Anti-VEGF AgentsR01EY029298 · NEI · THE TRUSTEES OF THE STEVENS INSTITUTE OF TECHNOLOGY · PI KANG-MIELER, JENNIFER J · 2019 to 2023
$2.7M
NEI NIH HHS R01 EY029298
6 · The paper itself

Abstract

purposeIntravitreal injections of anti-vascular endothelial growth factors (anti-VEGF) are the current standard of care for patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). There is a growing subset of patients that does not respond to anti-VEGF monotherapy treatment. Some patients, however, do respond to combination therapy of corticosteroids and anti-VEGF. This treatment requires monthly/bimonthly injections of anti-VEGF and semi-annual injections of corticosteroid. A drug delivery system (DDS) that simultaneously releases multiple drugs could benefit these patients by reducing the number of injections. The purpose of this study was to characterize the simultaneous release of aflibercept and dexamethasone from a biodegradable microparticle- and nanoparticle-hydrogel DDS.

methodsDexamethasone-loaded nanoparticles and aflibercept-loaded microparticles were created using modified single- and double-emulsion techniques, respectively. Then, microparticles and nanoparticles were embedded into a thermoresponsive, biodegradable poly(ethylene glycol)-co-(L-lactic acid) diacrylate (PEG-PLLA-DA)-N-isopropylacrylamide (NIPAAm) hydrogel DDS. Drug release studies and characterization of DDS were conducted with varying doses of microparticles and nanoparticles.

resultsThe combination aflibercept-loaded microparticle- and dexamethasone-loaded nanoparticle- hydrogel (Combo-DDS) achieved a total release time of 224 days. Small decreases were seen in swelling ratio and equilibrium water content for Combo-DDS compared to monotherapy aflibercept-loaded microparticle-hydrogel DDS (AFL-DDS) and monotherapy dexamethasone-loaded nanoparticle-hydrogel DDS (DEX-DDS). Bioactivity of aflibercept was maintained in Combo-DDS compared to AFL-DDS.

conclusionsThe Combo-DDS was able to extend and control the release of both aflibercept and dexamethasone simultaneously from a single DDS. This may eliminate the need for separate dosing regiments of anti-VEGF and corticosteroids for wet AMD patients.

Indexed as

Angiogenesis InhibitorsWet Macular DegenerationDexamethasoneDrug Delivery SystemsHumansHydrogelsIntravitreal InjectionsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsafliberceptAngiogenesis InhibitorsDexamethasoneHydrogelsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion Proteinsanti-VEGFControlled releasecorticosteroiddrug delivery systemneovascularization

Identifiers

PMID35343355
PMCPMC9906966
OpenAlexW4220988070

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.